Despite growing global fears about potential side effects, the Presidential Task Force on COVID-19 has stated that the Oxford-AstraZeneca COVID-19 vaccine is safe for Nigerians.
Dr. Mukhtar Muhammad, the PTF on COVID-19’s National Incident Manager (NIM), declared this at the taskforce’s joint national briefing on Monday in Abuja.
Clinical studies, according to Muhammad, have shown that the side effects are “generally mild.”
He stated that the WHO had vouched for the vaccine’s protection and effectiveness in the last three days through a series of briefings, and that it had been shown to have a 70 percent efficacy rating.
He did, however, warn those who may have administered the vaccine but have been exhibiting signs of its reactions for more than 24 hours to contact their state’s relevant authorities.
“The arrival of the vaccines is something that is very good and exciting in the sense that a combination of the vaccine and the non-pharmaceutical interventions can help us see the light at the end of the tunnel within a very short period of time.
“However, we have suffered a major setback in the last few hours regarding the content safety and efficacy of the Oxford AstraZeneca vaccine.”
“We have seen in the news how some countries have deferred the usage of this vaccine or have suspended its use. That list of the European countries is growing.”
“However, it is very reassuring to see that the regulatory agencies in those countries have continued to emphasise that the vaccine is safe and that the incidence of blood clots reported in the patients is not higher than the risk of blood clotting in people who are not vaccinated. That is really something reassuring.”
Despite the fact that medication authorities and the WHO say there is no evidence of a problem, several European countries have suspended the Oxford/AstraZeneca COVID-19 vaccine due to fears that it may cause blood clots.
On Monday, Germany, Italy, France, Spain, and the Netherlands became the new countries to halt the vaccine’s distribution.
Last week, Norway, Denmark, and Bulgaria put their programs on hold.